Clinical Trial

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at…

3 months ago

A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 (liafensine) for Treatment-Resistant Depression Published in JAMA Psychiatry

The study represents the first successful prospective genetic biomarker-guided drug trial in psychiatrySAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) --…

3 months ago

RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma

Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to advance innovative Theranostic radiopharmaceuticals to address unmet needs…

3 months ago

GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer

Scientific Advisory Board member, Dr. Noriyuki Kasahara, appointed Chief Scientific Officer of GenVivo, to accelerate the achievement of major clinical…

3 months ago

Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101

Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH)Findings suggest BIOX-101…

3 months ago

Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025

NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope®…

3 months ago

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in…

3 months ago

Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM…

3 months ago

Hemogenyx Pharmaceuticals PLC Announces Invitation to Participate at DCNY Summit

Hemogenyx Pharmaceuticals Invited to Participate at DCNY Summit LONDON, UK / ACCESS Newswire / September 11, 2025 / Hemogenyx Pharmaceuticals…

3 months ago

Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share

Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous…

3 months ago